Sporadic early-onset Alzheimer’s disease (EOAD) is rare and understudied

Getty Images

October 19, 2023 — Alexandra Touroutoglou, PhD, and Bradford Dickerson, MD, neuroscientists in the department of Neurology at Massachusetts General Hospital, are the lead authors of a new study published in Alzheimer’s & Dementia, The Sporadic Early-onset Alzheimer’s Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) Cohort.  

What Question Were You Investigating? 

Is there a signature biomarker for younger/early-onset Alzheimer’s Disease (EOAD)? 

Sporadic early-onset Alzheimer’s disease (EOAD) is rare and understudied. However, it is known to be a devastating form of Alzheimer’s disease (AD) affecting patients often in their 40s and 50s at the peak of their productive life, when they may be balancing careers, family responsibilities and community roles. 

Previous neuroimaging studies have advanced our understanding of neurodegeneration in sporadic EOAD. Still, these studies have included small samples and have not focused on developing an MRI biomarker. 

This study defined an EOAD-signature MRI biomarker using data from a well-characterized discovery sample from Massachusetts General Hospital (MGH) and tested the hypothesis that it can be reproducible in a large validation sample of participants with EOAD. 

What Methods or Approached Did You Use? 

We obtained the data from two independent cohorts. The MGH EOAD cohort included 25 patients in the ongoing MGH Frontotemporal Disorders Unit Longitudinal Cohort. The second cohort included 211 patients enrolled in the 18-site multicenter Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) consortium, a collaboration led by Liana Apostolova, MD at Indiana University School of Medicine, Indianapolis, Brad Dickerson, MD of Massachusetts General Hospital, Boston, Gil Rabinovici, MD at the University of California, San Francisco, and Maria Carrillo, PhD of the Alzheimer’s Association. 

LEADS participants receive a standard clinical evaluation and Magnetic Resonance Imaging (MRI) scanning as well as amyloid and tau PET scanning and fluid biomarker assessments on an annual basis. 

What Were Your Findings? 

Using quantitative analysis of brain atrophy from MRI scans, we identified a signature pattern of distributed cortical atrophy in EOAD that replicated across two well-characterized independent samples: a discovery sample of 25 participants with EOAD from MGH and a large validation sample of 211 participants with EOAD from the multicenter LEADS consortium. 

In addition to reliability across the two samples, the EOAD signature demonstrated clinical validity against widely used measures of symptom severity and cognitive function, with greater atrophy associated with greater cognitive impairment. 

The EOAD signature accurately differentiated EOAD patients from healthy controls as well as patients with early-onset non AD conditions associated with cognitive impairment. 

What Are the Clinical Implications? 

We were able to prove that the EOAD signature is a clinically valid measure of AD-related neurodegeneration. 

Future work will focus on using the EOAD signature of regional atrophy to examine changes in the brains of patients over time. 

Follow-up studies will also explore the relationship between atrophy within the EOAD signature and impairments in different cognitive domains. 

For more information: https://www.massgeneral.org/ 


Paper Cited:

Touroutoglou et al. (2023). The Sporadic Early-onset Alzheimer’s Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) Cohort. Alzheimer’s Dement. 2023;1–15. Alzheimer's & Dementia: The Journal of the Alzheimer's Association.   


Related Alzheimer's Content:    

Research Suggests Specialized Brain Imaging can Unveil Mysteries of Alzheimer’s Disease, Other Disorders    

FDA Grants Accelerated Approval for Alzheimer’s Drug Aduhelm    

VIDEO: Researchers Use MRI to Predict Alzheimer's Disease    

Brain Iron Accumulation Linked to Cognitive Decline in Alzheimer's Patients    

Good Results for Alzheimer’s Imaging Agent    

NIH Augments Large Scale Study of Alzheimer’s Disease Biomarkers    

Alzheimer’s Association Launches New Website for IDEAS Study    

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment    

Impaired Glymphatic System May be Linked with Progression of Alzheimer's Disease, Finds New Study  

Radiologists Must Monitor Novel Alzheimer’s Treatment Side Effect 

Related Content

News | Cardiac Imaging

May 17, 2024 — The Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting found that the ...

Time May 17, 2024
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
News | Radiology Imaging

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
News | RSNA

May 7, 2024 — The Radiological Society of North America (RSNA) and the Radiological and Diagnostic Imaging Society of ...

Time May 07, 2024
News | Magnetic Resonance Imaging (MRI)

May 7, 2024 — The Magna Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting showed a ...

Time May 07, 2024
News | ARRS

May 7, 2024 — The American Roentgen Ray Society (ARRS) announced that Philip Costello, MD, the 118th ARRS President and ...

Time May 07, 2024
News | Treatment Planning

May 6, 2024 — Elekta announced the acquisition of Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent ...

Time May 06, 2024
News | Magnetic Resonance Imaging (MRI)

May 6, 2024 — Hvidovre Hospital has the world's first prototype of a sensor capable of detecting errors in MRI scans ...

Time May 06, 2024
Subscribe Now